Gallstone Decalcification and Dissolution Using Chenodeoxycholate and Citrate by Sali, Avni & Vitetta, Luis
HPB Surgery, 1990, Vol. 3, pp. 59-65
Reprints available directly from the publisher
Photocopying permitted by license only
1990 Harwood Academic Publishers GmbH
Printed in the United Kingdom
GALLSTONE DECALCIFICATION AND
DISSOLUTION USING CHENODEOXYCHOLATE AND
CITRATE
AVNI SALI* and LUIS VITETTA
Department of Surgery, The University of Melbourne, Repatriation General
Hospital, Heidelberg, Victoria, 3081, Australia.
(Received 29 March 1990)
Gallgtone dissolution may be possible only in selected patients. Patients with calcified or large gallstones
are not suitable for dissolution. Citrate is normally present in bile and an oral citrate load can increase
biliary citrate.
A combination of chenodeoxycholic acid (C.D.C.A.) and citrate has been shown to dissolve calcified
cholesterol gallstones in vitro. Patients with calcified or large gallstones were treated with a combination
of C.D.C.A. and citrate. Partial decalcification was achieved in seven out of twenty patients with
calcified stones (35%) and complete decalcification in four patients (20%). One of the patients with
large stones had complete dissolution.
Five patients who were suitable for C.D.C.A. treatment but did not respond were also treated with
C.D.C.A. and citrate. One of the patients in this latter group had complete dissolution. Oral citrate can
decalcify some calcified gallstones.
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INTRODUCTION
It is now well established that, if certain criteria are adhered to, patients with radio
lucent gall bladder stones can have their stones dissolved with oral bile acid
therapy. However, up to the present time it has not been possible to dissolve
calcified gallstones using oral treatment. The potential of gallstone lithotripsy in the
treatment of gall bladder stones and the subsequent need for dissolution of the
resulting gallstone fragments has increased interest in gallstone dissolution.
It was first shown in 1980 by Sali and co-workers that citrate is normally present
in bile and also that citrate concentration of bile can be increased by an oral citrate
load. Subsequent in vitro studies by this group have shown that calcified pigment
stones can be dissolved using citrate solutions alone and calcified cholesterol
gallstones can be dissolved using solutions containing both citrate and bile acid2’3.
The above findings stimulated a therapeutic trial to dissolve calcified gall bladder
gallstones using oral citrate and chenodeoxycholic acid (C.D.C.A.). A second
group of patients with large gallstones generally considered not suitable for
treatment with bile acid therapy plus a smaller group who were resistant to bile acid
therapy were also studied.
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METHODS AND RESULTS
Three groups of patients were treated for at least 6 months.
Group 1" 20 patients with calcified gall bladder stones (Table 1).
Table 1 Patients with calcified stones (Group 1)
Calci- Diameter Calcification Decalcification Duration
fled largest of
Patient Age stones stone Peri- Com- No Treatment
No. Sex (years) (No.) (cm) Central pheral Diffuse Partial plete Change (months)
F 64 3 1.8 + + 12
2 F 52 9 2 + + 6
3 F 47 10 0.3 + + 8
4 F 56 2.5 + + 9
5 F 29 2 + + 12
6 F 69 1 1.2 + + 7
7 M 63 > 20 0.6 + + 12
8 M 75 1.2 + + 12
9 M 65 > 20 0.5 + + 8
10 F 66 3 2.2 + + 24
11 F 32 7 1 + + 9
12 F 32 > 20 1.5 + + 12
13 F 57 4 1.2 + + 12
14 F 33 2 0.7 + + 18
15 F 69 2 1.4 + + 8
16 F 81 >20 0.2 + + 7
17 (EF 55 2 + + 12
18 F 37 1.5 + + 18
19 F 39 11 1.5 + + 18
20 F 48 2.5 + + 6
Did not have follow-up ultrasound.
Group 2:12 patients with stones greater than the 2 cm. (Table 2).
Table 2 Patients with large radiolucent gallstones (Group 2)
Diameter Dissolution
Calcified largest
Patient Age stones stone No
No. Sex (years) (No.) (cm) Partial Complete Change
Duration
oy
Treatment
(months)
M 33 2 2 +
2 M 51 2 2.2 +
3 F 45 2.2 +
4 M 41 2.3 +
5 M 38 5 3.0 +
6 F 54 2.2 +
7 F 41 > 20 2.2 +
8 F 50 2 2 +
9 M 52 1 2.3 +
10 F 23 2 2.3 +
11 F 29 2 +
12 M 75 2 2 +
24
12
12
12
8
12
12
12
9
18
12
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Group 3" 5 patients with stones less than 1.5 c.m. that had not responded to
C.D.C.A. treatment. (Table 3).
Table 3 Patients not responding to CDCA (Group 3) then treated with Citrate and CDCA
Diameter Treatment (months)
No. largest
Patient Age of stone CDCA + No
No. Sex (years) stone (cm) CDCA citrate Partial Complete change
Dissolution
F 40 0.8 6 9
2 F 37 5 0.4 6 6
3 M 59 0.5 6 6
4 F 63 8 1.5 6 6
5 F 62 .5 6 12
Both Group One and Two are generally regarded as unsuitable for treatment
with bile acid therapy alone.
The Group 3 patients were initially treated with C.D.C.A. alone and after no
response at the end of 6 months they were treated with a combination of C.D.C.A.
and citrate. For all groups of patients the dose of C.D.C.A. was 14-16 mg per
kilogram given in two doses daily, whereas the dose of citrate was 90 mmol per day,
also given in two doses. A number of patients withdrew from the study before three
months and they have not been included in the treatment group. From Group 1, 7
patients ceased treatment because of diarrhoea, and another two patients stopped
treatment as one required a cholecystectomy and the other had to have surgery for
an aortic aneurysm. Diarrhoea is a well recognized problem in up to 40% of
patients having C.D.C.A. Ursodeoxycholate (U.C.D.A.) has not been available in
Australia. In Group 2, one patient ceased treatment because of diarrhoea and
another two were unable to tolerate the citrate taste which was given to the patients
in liquid form. Another patient decided to have a cholecystectomy after being on
dissolution treatment for five months. No patients withdrew from the third group.
Clinical details of the patients remaining in the three groups are shown in Tables 1-
3.
All patients had an oral cholecystogram as well as an ultrasound before starting
treatment to ensure that they had a functioning gall bladder. Blood was taken
before treatment was started and again six weeks later for liver function tests
(serum bilirubin, alanine transaminase, gamma glutamyl transpeptidase and
alkaline phosphatase), haemoglobin, white blood and platelet counts, and electro-
lytes (sodium, potassium, bicarbonate, urea, creatinine, calcium, phosphate).
The effect of the combination treatment of C.D.C.A. and citrate on gallstone
dissolution, decalcification or disappearance was assessed by a follow-up oral
cholecystogram as well as ultrasonography after six months treatment. Treatment
was generally well tolerated. Of the patients in Group 1, partial decalcification in
seven of the twenty patients (35%) was achieved. Complete decalcification
occurred in four (20%) of 20 patients and two of these patients had no stones on
oral cholecystography. Of these latter two patients, one had smaller stones on
ultrasonography but the other patient, who was from a distant town, refused to
have an ultrasound because of the necessary travel. Complete dissolution occurred
in one patient in Group 2 and partial dissolution occurred in two patients. One of62 A. SALI AND L. VITETTA
the five patients in Group 3 had complete dissolution. No haematological abnorma-
lities or persistent bio-chemical evidence of hepatotoxicity was noted in any of the
patients.
DISCUSSION
Although this was not a controlled study it showed an interesting response to
treatment with a combination of C.D.C.A. and citrate in patients with calcified
stones. Complete decalcification occurred in four (20%) and partial decalcification
in seven (35%). Radio opaque gallstones do not dissolve with oral bile acid therapy
whether calcification is present in the periphery, centre or throughout the stones. A
few gallstones with a tiny calcified nucleus of less than 3 mm. in diameter have been
reported to have been dissolved with bile acid therapy. It is very likely that these
small stones passed into the duodenum without the calcified centre being dissolved.
Calcified rims of gallstones can be partially decalcified with Rowachol, which is an
essential oil preparation5.
Oral citrate is excreted in pancreatic juice and citrate has been shown to dissolve
calcified pancreatic stones both in vitro and in humans6’7. The mode of action of
citrate in the dissolution of pancreatic stones may be similar to that which
decalcifies calcified gall bladder stones. Citrate is known to form soluble complexes
with calcium and therefore calcified stones are probably decalcified because of this
characteristic.
Four patients had complete decalcification of their stones as judged by X-ray.
However, three of these patients had stones still present on ultrasonography. It is
possible that the patient with small diffusely calcified stones had calcified pigment
stones with a lattice resisting dissolution remaining after calcium and, perhaps,
cholesterol removal.
It was disappointing that there was a poor response with citrate and C.D.C.A.
therapy in those patients with stones too large to be suitable for bile acid treatment
alone. There was also a poor response in those with smaller radiolucent stones
where there had been no response to C.D.C.A. therapy alone. Only one of the
patients with large radiolucent stones had complete dissolution and another partial
dissolution. One of the five patients with stones resistant to C.D.C.A. therapy had
complete dissolution of her stone when citrate was added to the treatment. It is
possible that three of the non-responders in this latter group of patients may have
had black pigment stones as their stones were less than 8 mm in diameter, although
only one of these patients had multiple stones. The other non-responder had eight
stones, all of which were approximately 1.5 cm in diameter. It is therefore likely
that more than six months therapy with C.D.C.A. and citrate was necessary to
achieve a response in this latter patient.
The majority of radiolucent stones that do not respond to C.D.C.A. therapy
have significant calcium compound on the stone surface which would prevent
cholesterol dissolutions. It had been hoped that a better response rate would have
been achieved as we were able to dissolve calcified cholesterol stones in vitro using
bile acid and citrate but not by using bile acid alone2’3. Calcium bilirubinate is the
principle pigment of pigment gallstones and an amorphous matrix of calcium
bilirubinate and protein has been found at the centre of most cholesterol
gallstones9’. It is likely that this central nucleus of calcium bilirubinate is importantGALLSTONE DISSOLUTION AND CITRATE 63
for cholesterol precipitation and stone formation. Therefore the concentration of
citrate which is normally present in bile may be an important factor in maintaining
calcium solubility and hence the prevention of gallstone formation. Oral citrate has
been used to prevent the formation of calcified kidney stones and it may be possible
to use citrate for the prevention of gallstone recurrence following dissolution11.
Citrate and C.D.C.A. may also be useful in dissolving calcified gallstone
fragments following lithotripsy.
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INVITED COMMENTARY
The fact that gallstones are not homogeneous in their chemical composition poses a
significant problem for gallstone therapy. The presence of calcium salts, mainly
carbonate and/or bilirubinate, in cholesterol gallstones has been recognized as a
strong negative factor for dissolution treatment with bile acids1. Precipitated
calcium salts may be present in the centre of stones, after acting as nucleating
factors to initiate gallstone growth, or calcification may occur on the surface or rim
of cholesterol gallstones after a period of stone growth. Bile acid treatment with
ursodeoxycholic acid, but not chenodeoxycholic acid, may actually promote stone
calcification, which has been observed in up to 12% of patients taking ursodeoxy-
cholic acid orally2’3.
In an effort to overcome the inhibitory effect of calcification on stone dissolution,
45 several potential stone solvents have been investigated in laboratory studies’. In
particular, the calcium-chelating agent ethylenediamine-tetra acetic acid (EDTA)
has been examined as an alternating treatment with bile acids, but bile acid-EDTA64 A. SALI AND L. VITETTA
solutions were not found to be effective on calcified cholesterol stones4. Although
pigment stones are disaggregated by bile acid-EDTA treatment in vitro4, no in vivo
studies have been performed to assess the efficacy of this combination for gallstone
dissolution. The work of Sali and Vitetta is therefore of interest because citrate may
act as a calcium-chelating agent in a similar fashion to EDTA, and it has been
previously shown that an oral citrate load can increase the citrate concentration in
bile.
The most important finding of the work of Sali and Vitetta is that a high
incidence of stone decalcification was observed after combined treatment with oral
chenodeoxycholic acid and citrate for at least six months. Unfortunately this was
not associated with a noticeable increase in the incidence of gallstone dissolution
over the low incidence which was expected from chenodeoxycholic acid treatment
alone. This finding is somewhat surprising and suggests that either calcification was
not the main factor preventing gallstone dissolution in many patients or that longer
treatment may have been required to effect dissolution. Thus, it has not been
shown that oral citrate is of any benefit in promoting gallstone dissolution with
chenodeoxycholic acid, but it is theoretically possible that it could be useful in
preventing gallstone recurrence in successfully treated patients, since calcium
solubility in bile is likely to be of critical importance in the formation of gallstones6.
Malcolm J. Whiting, PhD., M.A.A.C.B.,
Department of Biochemistry and Chemical Pathology,
Flinders Medical Centre,
Bedford Park, South Australia, 5042.
References
1. Schoenfield, L.J., Lachin, J. (1981) The Steering Committee, and the National Co-Operative
Gallstone Study Group: Chenodiol (Chenodeoxycholic acid) for dissolution of gallstones: The
National Co-Operative Gallstone Study. Ann. Int. Med. 95, 257-82
2. Podda, M., Zuin, M., Battezzati, P.M. et al. (1989) Efficacy and safety of a combination of
chenodeoxycholic acid and ursodeoxycholic acid for gallstone dissolution: a comparison with
ursodeoxycholic acid alone. Gastroenterology, 96, 222-9
3. Bateson, M.C., Bouchier, I.A.D., Trash, D.B. et al. (1981) Calcification of radiolucent gallstones
during treatment with ursodeoxycholic acid. Brit. Med. J., 283, 645-6
4. Leuschner, U., Wosiewitz, U., Baumgartel, H., et al. (1988) Dissolution of calcified cholesterol
stones and of brown and black pigment stones of the gallbladder. Digestion, 39, 100-10
5. Wosiewitz, U., Guldutuna, S., Fischer, H. et al. (1989) Pigment gallstone dissolution in vitro.
Scand. J. Gastro. 24, 373-80
6. Rege, R.V., Moore, E.W. (1986) Pathogenesis of calcium-containing gallstones. J. Clin. Invest.
77, 21-6
INVITED COMMENTARY
Gallstone dissolution is appropriate for fewer than one in three patients with
gallstones1. Complete dissolution of calculi will subsequently occur in only 50% of
the patients treated. Even if the stones are successfully dissolved life table analysis
shows a cumulative recurrence rate of 10% a year over the first 4 years2. PossibleGALLSTONE DISSOLUTION AND CITRATE 65
reasons for incomplete dissolution include gallstone size and composition, patient
compliance, and inability to unsaturate cholesterol from the bile.
The authors have addressed two groups of patients not usually amenable to
dissolution therapy- those with calcified and large calculi. Encouraged by earlier
in vitro studies where they were able to decalcify stones containing up to 20%
calcium, Sali and Vitetta have added an oral citrate load to chenodeoxycholic acid
(CDCA). Thirty seven patients completed the treatment protocol, whilst 9 with-
drew from Group 1 and 4 from Group 2. An optimal dose ofCDCA was used1. The
time period chosen for the study allowed sufficient time for large stones to dissolve.
The most important findings were from Group i where 4 patients showed complete
decalcification of their gallstones and the effect was not restricted to small stones.
Whether the effect of citrate is direct or whether it acts as an adjunct to CDCA, as
terpenes do, is not clear. Treatment of patients with large stones with this
combination of CDCA and citrate was less promising. Only 3 of the 12 patients
responded despite a median of 12 months treatment.
The authors have demonstrated a means of de-calcifying and subsequently
dissolving some calcified gallstones. Whilst further studies will be needed to
confirm these preliminary findings, the ability to dissolve calcified stones has been
demonstrated in oivo for what appears to be the first time. In the meantime,
cholecystectomy remains the gold standard against which non-operative techniques
must be judged.
Michael Hollands
Department of Surgery
Westmead Centre
WESTMEAD, NSW 2145
Australia
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